SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Stemline Therapeutics, Inc.' Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm